Overview

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Status:
Completed

Trial end date:
2020-10-02

Target enrollment:

Participant gender:

Summary

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Phase:

Phase 3

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Antibodies
Antibodies, Monoclonal
Brentuximab Vedotin
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Vincristine